AgeneBio

AgeneBio develops innovative therapeutics that prevent neurodegeneration and preserves cognitive function.

[AgeneBio @AgeneBio]

AgeneBio founder Michela Gallagher to speak on emerging #Alzheimers therapies at @ASENT_Org 2018 Annual Meeting https://t.co/XwxOQdd32l

[AgeneBio @AgeneBio]

AgeneBio founder Michela Gallagher to speak at 2018 @NIH #Alzheimers Research Summit on March 2 https://t.co/ln1skbTpA3 #ADSummit18

[AgeneBio @AgeneBio]

AgeneBio receives NIH grant to initiate Phase 3 HOPE4MCI trial to treat MCI due to #Alzheimers disease https://t.co/Y1quCNt6NY

[AgeneBio @AgeneBio]

AgeneBio receives up to $10M in NIH funding to advance program for mild cognitive impairment due to #alzheimers https://t.co/EOQHvba9Ys

[AgeneBio @AgeneBio]

Thanks 2 @TheADDF 4 another grant--will fund GABA-A drug-discovery program to delay onset of #Alzheimers dementia https://t.co/NDTzPbI63I

[AgeneBio @AgeneBio]

Our new corporate presentation is loaded on https://t.co/Hqyqi69m5j #Alzheimers

[AgeneBio @AgeneBio]

CEO Jerry McLaughlin presenting today at 3:35pm in NYC @ Neuroscience BioPartnering & Investment Forum https://t.co/ukeFtHp6NF #Alzheimers

[AgeneBio @AgeneBio]

Looking fwd 2 tomorrow's Neuroscience BioPartnering & Investment Forum CEO Jerry McLaughlin to present https://t.co/ukeFtHp6NF #Alzheimers

[AgeneBio @AgeneBio]

CEO Jerry McLaughlin 2 present @ Neuroscience BioPartnering & Investment Forum https://t.co/ukeFtHp6NF #Alzheimer #Phase3 #aMCI

[AgeneBio @AgeneBio]

Looking forward 2 @IAmBiotech CEO & Investor Conf our CEO on tap Feb 8 10:15am NYC https://t.co/UbGCK8mSfU #alzheimers #phase3

[AgeneBio @AgeneBio]

AgeneBio CEO Jerry McLaughlin to present at @IAmBiotech CEO & Investor Conf Feb 8 10:15am NYC https://t.co/UbGCK85hom #alzheimers #phase3

[AgeneBio @AgeneBio]

We've shared a new corporate deck on https://t.co/Lu8C5SsxVD and on SlideShare https://t.co/1AEEPKnZZA #Alzheimers

[Ian Kremer @LEAD_Coalition]

Check out the new @AgeneBio Phase 3 #clinicaltrial website for prevention/delay of #Alzheimers/#dementia: https://t.co/2J6TLGgJ5a

[AgeneBio @AgeneBio]

AgeneBio launches new https://t.co/69x5MewfME Phase 3 clinical website for prevention/delay of Alzheimer’s dementia #Alzheimers

[AgeneBio @AgeneBio]

We've shared a new corporate deck on our https://t.co/Lu8C5SsxVD and on SlideShare https://t.co/dGOYpv5tHm #Alzheimers

[AgeneBio @AgeneBio]

Thanks, Ian. Excited to be a member of @LEAD_Coalition. https://t.co/NSg8xEIMum

[Ian Kremer @LEAD_Coalition]

Thrilled to welcome our newest member organizations: @SecondWindDream @n4aACTION @AgeneBio! #dementia #Alzheimers #caregiving #innovation

[AgeneBio @AgeneBio]

We welcome the distinguished Dr. Richard Mohs as our VP, Clinical Development for #Alzheimer's Phase3 HOPE4MCI trial
https://t.co/R0Ctn1kAe2

[AgeneBio @AgeneBio]

.@alzforum reviews our own Dr. Gallagher's CTAD session on new #Alzheimers Phase 3 #clinicaltrials
https://t.co/FKVbaGsGzW

[AgeneBio @AgeneBio]

AgeneBio CEO Jerry McLaughlin to present @ Future of Innovation in Medicine Conference @gatesfoundation
https://t.co/o1y9Mfva1A #Alzheimers

[AgeneBio @AgeneBio]

AgeneBio to Present as a Top Project to Watch: Most Licensable Products in Neuroscience @ TAP Conference https://t.co/eaaNsJPT8y #Alzheimers